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See Article, pages 1351–1355When hepatologists begin their investigations at the scene of
liver damage, iron is certainly on the list of ‘‘usual suspects’’ to
be rounded up. Hemochromatosis, a well-known cause of chronic
liver disease, is the most prevalent genetic disorder in adults [1].
Serum iron parameters are therefore included in most guidelines
on how to investigate patients with elevated transaminases or
chronic liver disease [2].
The hemochromatosis (HFE) genotype is an important piece of
evidence in patients with liver disease and elevated transferrin
saturation with hyperferritinemia, because homozygosity for
the C282Y allele of HFE is considered sufﬁcient to diagnose hemo-
chromatosis under these circumstances [1]. Compound heterozy-
gosity for C282Y and H63D has been almost removed from the
watch-list and is currently considered a mere risk factor for liver
diseases – sufﬁcient to cause hemochromatosis or even cirrhosis
only in combination with other health burdens. Hence, a partner
in crime for HFE mutation must be found in patients with liver
disease and C282Y/H63D compound heterozygosity [3].
If there is evidence for iron overload in the absence of hemo-
chromatosis-associated HFE genotypes and the hepatopathologist
ﬁnds iron conﬁned to hepatocytes, sharp investigators are well
advised to search for the culprit in the genes encoding transferrin
receptor 2 (TFR2) and ferroportin (SLC40A1) or even to hunt for
combined mutations in these genes if a patient presents with
severe iron overload or early-onset disease [4]. If the patient is
adolescent or before the 3rd decade of life and presents with
heart failure or hypogonadism in addition to – often overlooked
– liver disease, other genes will be committed in custody. Muta-
tions in HJV and HAMP, which respectively encode hemojuvelin
and hepcidin, will be sufﬁcient to identify juvenile hemochroma-
tosis [5].
Through the power of genetics, iron-related diseases are now
subject to close scrutiny. In addition, genetic studies have greatly
advanced our understanding of hemochromatosis. This progress
is reﬂected in the proposed re-classiﬁcation of human ironJournal of Hepatology 20
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the unifying feature of all disorders with hepatocellular iron
accumulation [6].
Primary hepcidin deﬁciency results from mutation in HAMP.
Secondary hepcidin deﬁciency is found in patients with muta-
tions in HFE, TFR2, or HJV. Deﬁciency in the effects of hepcidin,
or resistance to hepcidin’s effects, through certain SLC40A1muta-
tions can be an alternative cause of hepatocellular iron overload
[7,8]. Like genetic syndromes causing hepcidin alterations,
acquired conditions can also result in hepcidin deﬁciency or
hepcidin resistance. Liver dysfunction non-speciﬁcally causes
hepcidin deﬁciency, which explains the iron overload frequent
in end-stage liver disease. Finally, recent studies suggest that in
patients with dysmetabolic iron overload syndrome, acquired
hepcidin resistance is involved in the pathogenesis of iron load-
ing [9].
This new classiﬁcation of adult and juvenile as genetic or
acquired hemochromatosis – hepcidin-deﬁcient or hepcidin-
resistant – embraces all iron overload syndromes except neonatal
hemochromatosis (NH). Despite its high recurrence rate in sib-
lings of affected patients, this disorder has evaded genetic recon-
naissance [10]. NH until recently was an enigmatic condition in
which affected patients typically present with liver failure during
their ﬁrst days of postnatal life and on histopathologic study
exhibit siderosis of epithelia (most prominently of acini of minor
salivary glands, thyroid, and pancreas) and of myocardium, with
at worst scant reticuloendothelial-cell siderosis. An antioxidant
cocktail with iron chelators is a small hope for cure or may help
to bridge the time to liver transplantation in this usually fatal dis-
order [11]. Recurrence of NH after liver transplantation has not
been described (Fig. 1).
Findings reported in this issue of the Journal of Hepatology
now position NH within the matrix of a hepcidin-based hemo-
chromatosis classiﬁcation, lodging it in the ‘acquired hepcidin
deﬁciency’ group. This is one major implication of the ﬁndings
from Silvana Bonilla, Joshua D. Prozialeck and their team from
Peter Whitington’s group at Chicago’s Northwestern University
[12]. They report the expression of iron genes in various tis-
sues from a small series of patients with neonatal liver failure,
all of whom had a sibling with histologically proven NH. The
expression of hepcidin, the main iron regulatory peptide, in12 vol. 56 j 1226–1229
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Fig. 1. Clinical manifestation and proposed pathophysiology of neonatal hemochromatosis. (A) Abdominal T2 weighted MRI of a 26-year-old female in the 40th week
of her second pregnancy. The arrow indicates the dark liver compatible with fetal liver iron loading. After birth, the newborn presented with neonatal liver failure and
evidence of iron overload (serum iron parameters: ferritin 8988 lg/L, transferrin 98 mg/dl and transferrin saturation 100%). Picture courtesy of Prof. Michael Schocke
(Department of Radiology, Medical University of Innsbruck). (B) Proposed pathophysiology of neonatal hemochromatosis. (Left panel) Iron transport across the normal
placenta, where maternal transferrin bound iron is taken up through transferrin medicated endocytosis at the apical (maternal) membrane of the syncytiotrophoblast,
which is released at the basolateral membrane by ferroportin and binds to fetal transferrin. Iron release is controlled by the fetus through fetal hepcidin, which inhibits
ferroportin. (Right panel) Iron transport across the placenta of a fetus with neonatal hemochromatosis. Reduced fetal hepcidin and reduced transferrin concentration are
proposed to result in dysregulated transplacental iron transfer and increased non-transferrin bound iron, which is toxic and primarily stored in tissues with high expression
of the transition metal transport protein ZIP14 and low expression of the iron export protein ferroportin.
JOURNAL OF HEPATOLOGYlivers from infants with NH was <20% of that in normal neo-
natal liver tissue, which provides a clue to the pathogenesis of
NH.Journal of Hepatology 2012As in adult and juvenile hemochromatosis, where hepcidin
deﬁciency is believed to mediate increased absorption of dietary
iron, hepcidin deﬁciency in NH might be expected to dysregulatevol. 56 j 1226–1229 1227
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transfer of iron across the placenta, which is equipped with the
same iron transporters as the gut. Evidence from the hepcidin
knockout mouse shows that hepcidin modulates iron transport
across the placenta [13] although hepcidin deﬁciency is not
known to cause fetal liver disease and, indeed, iron overload in
hepcidin-deﬁcient mice appears to be a postnatal phenomenon
[14].
Iron is transferred across the placenta through the hepcidin
receptor ferroportin, which releases ferrous iron. After oxidation
of ferrous iron by ceruloplasmin, the metal is bound by transfer-
rin. Transferrin, which is – like hepcidin – mainly produced in the
liver, is also signiﬁcantly reduced in NH. Hypotransferrinemia,
perhaps potentiated by increased transplacental iron transfer,
in a toxic alliance with reduced fetal hepcidin, results in
increased non-transferrin-bound iron (NTBI). NTBI is implicated
in the hemochromatotic siderosis of atransferrinemia [15,16], a
condition in which hepcidin handling has not been studied. Are
NTBI concentrations elevated in fetuses and infants with NH?
An anecdotal report suggests that they may be [17]. Determina-
tions of NTBI [18] nowadays approaching the clinical routine
[19] are yet to be performed systematically in NH patients. Nor
has plasma hepcidin been quantitated in such patients.
To explain the distinct pattern of iron overload in NH, the
Northwestern University investigators further assessed iron
transport protein expression in extrahepatic tissues of affected
infants and control tissue. Tissues most severely iron-loaded in
NH, such as epithelium of pancreatic acini or thyroid follicles,
stained strongly for the metal transport protein ZIP14, encoded
by SLC39A14, but did not mark substantially for the iron export
protein ferroportin. Further evidence in support of ZIP14 as an
iron transporter of importance came from co-localization studies
showing that cells with increased stainable iron express ZIP14.
The interplay between ZIP14 and NTBI remains unclear [12].
Case closed? Perhaps not. One must bear in mind that this
study was limited to patients with gestational alloimmune liver
disease (GALD)-associated NH (GALD-NH). Immunohistochemi-
cal analysis of liver of affected infants showed deposition of com-
plement factors as pathognomonic in GALD [20]. Based on the
hypothesis that NH is generally caused by maternal antibodies
against a fetal liver antigen, administration of intravenous immu-
noglobulin has been shown to ameliorate or even to prevent
recurrence of NH within sibships [21].
GALDmight be one of the commonest causes of NH, but a phe-
notype of neonatal liver failure with signiﬁcant hepatic and
extrahepatic iron overload is not exclusive to GALD-NH. Mito-
chondrial DNA depletion syndromes [22,23] or Down syndrome
with megakaryocytic transient myeloproliferative disorder
[24,25] also are associated with a NH phenotype.
These ﬁndings support the hypothesis that any genetic,
immunological or metabolic defect that causes intrauterine liver
failure will result in both hypotransferrinemia and low fetal hep-
cidin expression, perhaps with dysregulated iron transfer across
the placenta from the mother to the fetus. Support for this
hypothesis comes from reports of infants with NH whose moth-
ers developed severe and refractory gestational iron deﬁciency
[26]; in contrast, however, are ﬁndings in earlier quantitative
work indicating that redistribution of iron within the conceptus
– away from the liver and into other sites – rather than absolute
iron overload is found in NH [27].
Is NH therefore a ﬁnal common manifestation of intrauterine
liver failure rather than a deﬁned disease entity? This would1228 Journal of Hepatology 2012explain why it has been impossible to identify a genetic cause
of NH [10] or even to deﬁne a clear mode of inheritance.
NH is a devastating condition. Progress in treatment and pre-
vention of NH also includes improving the diagnosis. Findings
reported here suggest a model in which fetal hepcidin deﬁciency
contributes to NH. Novel therapeutic developments could there-
fore aim at reducing transplacental iron transport or aim at sup-
plementing fetal hepcidin – possibly with recently developed
mini-hepcidins [28]. The most immediate implications, however,
of recent developments and current ﬁndings regarding NH in
clinical practice are probably that NH is better recognized as a
syndrome rather than as an independent entity and that physi-
cians and researchers involved in the care of NH patients and
affected families must continue investigations to identify the
underlying cause of liver failure to improve patient care and for
correct counseling. Quantitative studies of NTBI and hepcidin lev-
els in NH, for instance, will be of considerable value in under-
standing the abnormalities in iron handling that mark the
disorder.
Beyond basic research, accurate diagnosis of underlying con-
ditions is important. GALD, mitochondrial DNA depletion syn-
dromes and inborn errors of metabolism or hemopoiesis
associated with liver failure all may incite NH. Each condition
has a speciﬁc prognosis, recurrence rate, mode of inheritance
and management. Pediatric hepatologists and genetic counselors
are therefore well advised not to conclude their investigations
when ‘NH’ is diagnosed in an infant. To do so risks arresting only
the ‘hitman’ and not the ‘true offender’.Conﬂict of interest
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